|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM322325218 |
| 003 |
DE-627 |
| 005 |
20240229152836.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202007426
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1306.xml
|
| 035 |
|
|
|a (DE-627)NLM322325218
|
| 035 |
|
|
|a (NLM)33675268
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Zheng, Pan
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A Multichannel Ca2+ Nanomodulator for Multilevel Mitochondrial Destruction-Mediated Cancer Therapy
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 02.11.2021
|
| 500 |
|
|
|a Date Revised 26.02.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2021 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Subcellular organelle-targeted nanoformulations for cancer theranostics are receiving increasing attention owing to their benefits of precise drug delivery, maximized therapeutic index, and reduced off-target side effects. Herein, a multichannel calcium ion (Ca2+ ) nanomodulator (CaNMCUR+CDDP ), i.e., a cisplatin (CDDP) and curcumin (CUR) co-incorporating calcium carbonate (CaCO3 ) nanoparticle, is prepared by a facile one-pot strategy in a sealed container with in situ synthesized polydopamine (PDA) as a template to enhance Ca2+ -overload-induced mitochondrial dysfunction in cancer therapy. After systemic administration, the PEGylated CaNMCUR+CDDP (PEG CaNMCUR+CDDP ) selectively accumulates in tumor tissues, enters tumor cells, and induces multilevel destruction of mitochondria by the combined effects of burst Ca2+ release, Ca2+ efflux inhibition by CUR, and chemotherapeutic CDDP, thereby observably boosting mitochondria-targeted tumor inhibition. Fluorescence imaging of CUR combined with photoacoustic imaging of PDA facilitates the visualization of the nanomodulator. The facile and practical design of this multichannel Ca2+ nanomodulator will contribute to the development of multimodal bioimaging-guided organelle-targeted cancer therapy in the future
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a calcium-ion overload
|
| 650 |
|
4 |
|a cancer theranostics
|
| 650 |
|
4 |
|a mitochondrial dysfunction
|
| 650 |
|
4 |
|a multichannel calcium-ion nanomodulators
|
| 650 |
|
4 |
|a multimodal bioimaging
|
| 650 |
|
7 |
|a Antineoplastic Agents
|2 NLM
|
| 650 |
|
7 |
|a Calcium Channel Agonists
|2 NLM
|
| 650 |
|
7 |
|a Indoles
|2 NLM
|
| 650 |
|
7 |
|a Nanocapsules
|2 NLM
|
| 650 |
|
7 |
|a Polymers
|2 NLM
|
| 650 |
|
7 |
|a polydopamine
|2 NLM
|
| 650 |
|
7 |
|a Calcium Carbonate
|2 NLM
|
| 650 |
|
7 |
|a H0G9379FGK
|2 NLM
|
| 650 |
|
7 |
|a Curcumin
|2 NLM
|
| 650 |
|
7 |
|a IT942ZTH98
|2 NLM
|
| 650 |
|
7 |
|a Cisplatin
|2 NLM
|
| 650 |
|
7 |
|a Q20Q21Q62J
|2 NLM
|
| 700 |
1 |
|
|a Ding, Binbin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shi, Run
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jiang, Zhongyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xu, Weiguo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Gao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ding, Jianxun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Xuesi
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 33(2021), 15 vom: 05. Apr., Seite e2007426
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:33
|g year:2021
|g number:15
|g day:05
|g month:04
|g pages:e2007426
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202007426
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 33
|j 2021
|e 15
|b 05
|c 04
|h e2007426
|